Chengdu Leading Pharma receives funding support to develop innovative therapies.

Chengdu GenVol today announced a new partnership agreement with the Gates Foundation. Chengdu GenVol will use its industry-leading DNA-encoded compound library technology platform to screen new lead compounds for diseases such as tuberculosis, malaria, and others with unmet treatment needs, as well as to discover novel non-hormonal contraceptive drugs. Under the terms of the agreement, Chengdu GenVol will conduct DEL screening for 15 drug targets jointly identified by the Gates Foundation and its academic and research institution partners, with the drug discovery work being supported by funding from the Gates Foundation.